Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.57 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.57 |
| ▸ | F10 | P00742 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.49 |
| ▸ | NOS3 | P29474 | 4/20 | 0.48 |
| ▸ | NOS1 | P29475 | 4/20 | 0.48 |
| ▸ | NOS2 | P35228 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | ABAT | P80404 | 1/20 | 0.48 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7398643 | 0.98 | KMT2A (0.64) | KMT2ALOXL2LMNAHDAC3HDAC6 | |
| Ethylene SCHEMBL11090983 | 0.96 | KMT2A (0.61) | KMT2ALOXL2LMNAHDAC3HDAC6 | |
| SCHEMBL27361738 | 0.94 | KMT2A (0.59) | KMT2ALOXL2LMNAHDAC3HDAC6 | |
| Trifluoroacetic Acid SCHEMBL1823273 | 0.87 | KMT2A (0.52) | KMT2ALOXL2LMNAHDAC3HDAC6 | |
| Acetophenone SCHEMBL27933326 | 0.85 | LMNA (0.62) | KMT2ALOXL2LMNAKDM4ESMN1; SMN2 | |
| SCHEMBL8269164 | 0.84 | EPHX2 (0.69) | KMT2AHDAC3HDAC6NCOR2MAPT | |
| SCHEMBL378134 | 0.82 | KMT2A (0.61) | KMT2ALMNAHSD17B10KDM4ENOS3 | |
| SCHEMBL17132765 | 0.82 | KMT2A (0.61) | KMT2ALOXL2LMNAHSD17B10SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL7400678 | 0.80 | KMT2A (0.59) | KMT2ALMNAHSD17B10KDM4ENOS3 | |
| SCHEMBL6859304 | 0.80 | KMT2A (1.00) | KMT2ALMNAHSD17B10SMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2033662-B1 | Transglutaminase mediated conjugation of peptides | NOVO NORDISK HEALTHCARE AG (CH) | 2012-10-17 | — | — | EP | claimed |
| US-20230391794-A1 | MAYTANSINOID-BASED DRUG DELIVERY SYSTEMS | CENTURION BIOPHARMA CORPORATION | 2023-12-07 | — | — | US | disclosed |
| CN-116986985-A | Chalcone derivative and application thereof | 广州医科大学 | 2023-11-03 | — | — | CN | disclosed |
| WO-2023171448-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DISEASE TO BE PREVENTED OR TREATED BY DEACTIVATION OF MYOFIBROBLASTS | 学校法人東海大学 | 2023-09-14 | — | — | WO | disclosed |
| US-20230159554-A1 | COMPOUND WITH ANTICANCER ACTIVITY | KYOWA KIRIN CO., LTD. (JP) | 2023-05-25 | — | — | US | disclosed |
| US-11584747-B2 | Substituted pyridopyrimidinonyl compounds useful as T cell activators | SYNGENE INTERNATIONAL LIMITED (IN) | 2023-02-21 | — | — | US | disclosed |
| US-11572373-B2 | Maytansinoid-based drug delivery systems | LADRX CORPORATION (US) | 2023-02-07 | — | — | US | disclosed |
| WO-2021062246-A1 | CRF RECEPTOR ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. (US) | 2021-04-01 | — | — | WO | disclosed |
| WO-2021041588-A1 | SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-03-04 | — | — | WO | disclosed |
| US-20210061802-A1 | SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | SYNGENE INTERNATIONAL LIMITED (IN) | 2021-03-04 | — | — | US | disclosed |
| US-7176279-B2 | Cyclic peptide compositions and methods for treatment of sexual dysfunction | PALATIN TECHNOLOGIES, INC. (US) | 2007-02-13 | — | — | US | disclosed |
| US-20060258701-A1 | Novel 2-pyridinecarboxamide derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-16 | — | — | US | disclosed |
| EP-0882715-B1 | NOVEL N-(UNSUBSTITUTED OR SUBSTITUTED)-4-SUBSTITUTED-6-(UNSUBSTITUTED OR SUBSTITUTED)PHENOXY-2-PYRIDINECARBOXAMIDES OR THIOCARBOXAMIDES, PROCESSES FOR PRODUCING THE SAME, AND HERBICIDES | KUREHA CHEMICAL IND CO LTD (JP) | 2003-04-23 | — | — | EP | disclosed |
| US-6339045-B1 | CAN BE USED IN A SMALL AMOUNT, SHOWING A GOOD SELECTIVITY BETWEEN CROP AND WEED, AND CAUSING NO PHYTOTOXICITY | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 2002-01-15 | — | — | US | disclosed |
| WO-2000023444-A1 | 5,7-DISUBSTITUTED-4-AMINOPYRIDO[2,3-D]PYRIMIDINE COMPOUNDS | ABBOTT LABORATORIES (US) | 2000-04-27 | — | — | WO | disclosed |
| EP-0989986-A1 | 5,7-DISUBSTITUTED 4-AMINOPYRIDO 2,3-D]PYRIMIDINE COMPOUNDS AND THEIR USE AS ADENOSINE KINASE INHIBITORS | Abbott Laboratories (US) | 2000-04-05 | — | — | EP | disclosed |
| CN-1218399-A | Benzamide treatment of dementia associated with AIDs virus (HIV-4) infection | CENTAUR PHARMACEUTICALS INC (US) | 1999-06-02 | — | — | CN | disclosed |
| EP-0882715-A1 | NOVEL N-(UNSUBSTITUTED OR SUBSTITUTED)-4-SUBSTITUTED-6-(UNSUBSTITUTED OR SUBSTITUTED)PHENOXY-2-PYRIDINECARBOXAMIDES OR THIOCARBOXAMIDES, PROCESSES FOR PRODUCING THE SAME, AND HERBICIDES | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1998-12-09 | — | — | EP | disclosed |
| WO-1998046605-A1 | 5,7-DISUBSTITUTED 4-AMINOPYRIDO[2,3-D]PYRIMIDINE COMPOUNDS AND THEIR USE AS ADENOSINE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 1998-10-22 | — | — | WO | disclosed |
| EP-0031794-A2 | Cephalosporin derivatives, process for their preparation and pharmaceutical compositions containing them | CIBA-GEIGY AG (CH) | 1981-07-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584747-B2 | Substituted pyridopyrimidinonyl compounds useful as T cell activators | DGKZ, DGKA, DGKG | KMT2A 2162/4885LOXL2 3987/4885LMNA 2876/4885 |
| US-20210061802-A1 | SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | DGKZ, DGKA, DGKG | KMT2A 2162/4885LOXL2 3987/4885LMNA 2876/4885 |
| US-20230391794-A1 | MAYTANSINOID-BASED DRUG DELIVERY SYSTEMS | SLC6A2, SLC6A7, SLC6A4 | KMT2A 4652/4885LOXL2 3331/4885LMNA 3527/4885 |
| US-20230159554-A1 | COMPOUND WITH ANTICANCER ACTIVITY | TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RCC2 | KMT2A 2349/4885LOXL2 2834/4885LMNA 1695/4885 |
| US-11572373-B2 | Maytansinoid-based drug delivery systems | SLC6A2, SLC6A7, SLC6A4 | KMT2A 4652/4885LOXL2 3331/4885LMNA 3527/4885 |
| US-20060258701-A1 | Novel 2-pyridinecarboxamide derivatives | GCKR, GCK, HK2 | KMT2A 1311/4885LOXL2 2252/4885LMNA 4724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.